Integrated Biomarker and Imaging Study: To Assess the Ability of Rosuvastatin to Decrease Necrotic Core in Coronary Arteries.

Trial Profile

Integrated Biomarker and Imaging Study: To Assess the Ability of Rosuvastatin to Decrease Necrotic Core in Coronary Arteries.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms IBIS-3
  • Most Recent Events

    • 16 Nov 2016 Results (n=143) presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 09 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top